AI Terminal
NewMed Energy
Investor Presentation • Aug 8, 2024
7125_rns_2024-08-08_15f0e520-2383-4fa0-be8b-3dbc57fb4f5d.pdf
Investor Presentation
Open in ViewerOpens in native device viewer
2Q 2024 Financial Results Presentation
August 2024
Disclaimer
This presentation was prepared by NewMed Partnership (the "Partnership") and is given to you only for the provision of che sake of convenience and may not be copied or diser person. The Data and information included in this presentation should not be interpreted as advice and should not be relied on for any participle the copied or used except as express w permitted in writing.
This presentation does not purport to be comprehension which might be relevant in comection with the making of a decision on an investment in securities of the Partnership.
No explicit or implicit representation or uny person regarding the accuracy or interny of any information included in this presentation in particular, no representation or undertaking is given reasonableness of any forecasts regarding the future chances of the Partnership.
To obtain a full picture of the Partnership and the risks entalled thereby see the full immediate and periodic reports filed by the Partnership with the Israel Securities Authority and the Tel. A including warnings regarding forward-looking information, as defined in the Securities Law, 572-1988, included therein. The forward-colining in the presentation in whole or in part, or may materialize differently than expected, or may oe affected by factors that cannot be assessed in advance.
For the avoidance of doubt, it is clarifers in do not under and or modify the information included in the presentation to rellect events and/or circumstances occurring after the date of preparation of the presentation.
This presentation is not an offer or invitation to buy or surities. This presentation and anything contained herein are nota basis for any contract or undertaking and are not to be relied upon in such on ovided in the presentation is not a basis for the making of any mestment decision, no a recommendation or an opinion, nor a substitute for the discretion of a potentialinvestor.
Key Highlights
- □ 2ªd quarter gas production c. 1,105 MMcf/d (195 Mboe/d), 2.81 BCM
- □ 20d quarter earnings \$204mm EBITDA / \$137mm net profit
- □ Leviathan Operational Update :
- 3rd GL project, on time on budget .
- Condensate sales
-
- ▪ MOE preliminary green light for additional export quantities
- FEED commencement .
- Long lead items procurement .
- □ Dividend \$65mm Dividend distribution for the quarter.
Production Summary
| Israel | Egypt | Jordan | Total | |
|---|---|---|---|---|
| 20 / 2024 (BCM) | 0.4 | 1.87 | 0.6 | 2.8 |
| Average Price (\$/mmbtu) | 6.29 | |||
| 2Q / 2023 (BCM) | 0.3 | 1.6 | 0.6 | 2.5 |
| Average Price (\$/mmbtu) | 6.14 |
* Production Summary for Leviathan 100%
Price Environment
Leviathan Expansion
- ロ The Ministry of Energy has given a preliminary green light to expand the export of natural gas, while also increasing the supply to the domestic market. The export volume may be increased by an additional 118 BCM, which may increase to up to 145 BCM
- □ Phase 1B FEED Approved a decision regarding performance of the FEED and preliminary procurement of long lead items with an additional budget of approx. \$429 million (100%, the Partnership's share is approx. \$194.5 million)
- □ In parallel expanding Leviathan production capacity. Regional connectivity export pipelines also progressing.
- = expected during 2025.
- Preliminary budgets approval by Leviathan partners for a compressor station for the expansion of the regional transmission system, expected to commence 1H 26.
- = allocation at third of total capacity subject to GTA signed with INGL.
- □ Leviathan Partners are continuing to examine additional options for an FLNG facility solution.
Key 2nd Quarter Financial Metrics (smm)
EBITDA calculated as Operating profit + Deprecation and Amortization
P&L Summary (\$mm)-
NNA
| For the period | 4-6/2024 | 4-6/2023 | 2023 |
|---|---|---|---|
| Revenues From natural gas and condensate sales | 295.3 | 250.8 | 1,094.4 |
| Net of royalties | 42.6 | 36.4 | 159.8 |
| Revenues, net | 252.7 | 214.4 | 934.6 |
| Expenses and costs: | |||
| Cost of production of natural gas and condensate | 43.0 | 34.8 | 148.6 |
| Depreciation, depletion and amortization expenses | 19.3 | 20.9 | 79.2 |
| Other direct expenses | 1.3 | 0.9 | 5.3 |
| G&A | 4.9 | 5.8 | 20.8 |
| Total expenses and costs | 68.5 | 62.4 | 253.9 |
| The Partnership's share in the losses / Profits of a company accounted for at equity | 1.4 | (0.1) | (1.3) |
| Operating profit | 185.6 | 151.9 | 679.4 |
| Financial expenses | (29.4) | (31.9) | (133.8) |
| Financial income | 23.8 | 6.9 | 28.7 |
| Financial expenses, net | (5.6) | (25.0) | (105.1) |
| Profit before income taxes | 180.0 | 126.9 | 5/4.3 |
| Taxes on income | (43.6) | (34.0) | (142.8) |
| Profit from continued operation | 136.4 | 929 | 431.5 |
| Total profit from discontinued operations | 0.6 | 2.1 | |
| Net income | 137.0 | 929 | 433.6 |
2nd Quarter Change in Net Profit (\$mm)
Financial Debt (s'B)
□ NewMed's Leviathan Bond buy back amounts to \$44mm to date
Balance Sheet Summary (\$mm)
NNY
| For the Period Ending | 30.06.2024 | 30.06.2023 | 31.12.2023 |
|---|---|---|---|
| Assets: | |||
| Current assets: | |||
| Cash and cash equivalents | 111.5 | 69.0 | 29.1 |
| Short-term deposits | 190.0 | 18.0 | 157.6 |
| Trade receivables | 256.1 | 204.9 | 194.5 |
| Trade and other receivables | 155.3 | 128.2 | 187.1 |
| 712.9 | 420.1 | 568.3 | |
| Non-current assets: | |||
| Investments in oil and gas assets | 2,640.5 | 2,601.1 | 2,647.3 |
| Investments in a company accounted for at equity | 60.8 | 58.3 | 58.4 |
| Long-term deposits | 0.5 | 0.5 | 101.9 |
| Other long-term assets | 493.5 | 548.1 | 470.3 |
| 3,195.3 | 3,208.0 | 3,277.9 | |
| 3,908.2 | 3,628.1 | 3,846.2 | |
| Liabilities and equity: | |||
| Current liabilities: | |||
| Current maturities of bonds | 590.5 | ||
| Short term banks Loan | 80.0 | ||
| Income tax payable | 16.3 | 2.1 | 27.7 |
| Trade and other payables | 93.2 | 110.7 | 101.1 |
| Other short-term liabilities | 0.9 | 6.3 | 2.2 |
| 700.9 | 119.1 | 211.0 | |
| Non-current liabilities: | |||
| Bonds | 1.138.7 | 1.733.0 | 1,735.1 |
| Deferred taxes | 349.7 | 309.1 | 313.9 |
| Other long-term liabilities | 68.0 | 74.5 | 73.7 |
| 1,556.4 | 2,116.6 | 2,122.7 | |
| Equity: | |||
| Partners' equity | 154.8 | 154.8 | 154.8 |
| Capital reserves | (28.2) | (29.0) | (28.6) |
| Retained earnings | 1,524.3 | 1,266.6 | 1,386.3 |
| 1,650.9 | 1,392.4 | 1,512.5 | |
| 3,908.2 | 3,628.1 | 3,846.2 | |
Dividends
- ロ \$65mm profit distribution for the quarter
- □ \$910mm returned to unitholders in profit distribution from Leviathan start up*
Dividend Distributions
* Including latest declared Dividend
NN. Thank You NewMed Energy- IR Tel. +972 9 971 2421 [email protected]
Appendix
Leviathan Bond Sponsor Financial Data Report
| QUARTER ENDED | 30.06.2024 | |
|---|---|---|
| OUANTITY/ACTUAL | ||
| AMOUNT (IN USD\$ ,000) | ||
| Total Offtake (BCM) | 2.8 | |
| Leviathan Revenues (100%) | 651,218 | |
| Loss Proceeds, if any, paid to Revenue Account | ||
| Sponsor Deposits, if any, into Revenue Account | ||
| Gross Revenues (before Royalties) | 266,253 | |
| Overriding Royalties | ||
| Statutory Royalties | (30,333) | |
| (b) Third Party Royalties | (12,031) | |
| Net Revenues | 223,889 | |
| Costs and Expenses: | ||
| Fees Under the Financing Documents (Interest Income) | 1,292 | |
| Taxes | (28,905) | |
| Operation and Maintenance Expenses | (41,707) | |
| Capital Expenditures | (41,706) | |
| Insurance (income) | (10,556) | |
| Total Costs and Expenses (sum of Items H(a), (c), (c), (d) and (e)) | (121,582) | |
| Total Cash Flows Available for Debt Service (Item G minus Item H) | 102,307 | |
| Total Cash Flow from operation (Item G minus Items H(c) and H(e) | 171,262 | |
| Total Debt Service | 56,438 | |
| Total Distribution to the Sponsor | 49,000 |